Bibliography
- Cervantes F, Dupriez B, Pereira A, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
- Gangat N, Caramazza D, Vaidya R, DIPSS-Plus: a refined Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol 2011;29(4):392-7
- Martinez-Trillos A, Gaya A, Maffioli M, Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233-7
- Ianotto JC, Kiladjian JJ, Demory JL, PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 2009;146:223-5
- Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117(18):4706-15
- Mesa RA, Schwager S, Radia D, The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-203
- Barosi G, Rosti V, Vannucchi A. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother 2011;12(10):1597-611
- James C, Ugo V, Le Couedic JP, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8
- Verstovsek S, Kantarjian H, Mesa RA, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
- Santos FP, Kantarjian HM, Jain N, Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6
- Pardanani A, Gotlib JR, Jamieson C, Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29(7):189-96
- Pardanani A, Gotlib JR, Jamieson C, Longer-term follow-up with TG101348 therapy in myelofibrosuis confiorms sustained improvement in splenomegaly, disease-related symptoms, and JAK2V617F allele burden. ASH Annual Meeting Abstracts. Blood 2010;116:1271
- Verstovsek S, Deeg J, Odenike O, Phase 1 – 2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. ASH Annual Meeting Abstracts. Blood 2010;116:205
- Pardanani A, George G, Lasho T, A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. ASH Annual Meeting Abstracts. Blood 2010;116:206
- Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl negative myeloproliferative neoplasms. Leukemia 2008;22:1990-8